Ukuhlinzwa Kokwelapha Umdlavuza Wamaphaphu 2026: Ukuphumelela Okusha Kwe-Neo-Adjuvant 

Ukuhlinzwa kokwelashwa komdlavuza wamaphaphu ngo-2026 kuhlanganisa izindlela zokwelapha ezithuthukisiwe ze-neo-adjuvant ukuze kuthuthukiswe kakhulu imiphumela yesiguli ngaphambi kokuhlinzwa. Le ndlela ihlanganisa i-immunotherapy, izidakamizwa ezihlosiwe, kanye nokwelashwa ngamakhemikhali ukuze kuncishiswe izimila, kuqede ama-micro-metastases, futhi kwandise amathuba okususwa okuphelele kwesimila. Ukuphumelela kwakamuva kukhombisa ukuthi izindlela zokwelapha zangaphambi kokuhlinzwa manje seziyindinganiso yokunakekela izigaba eziningi zomdlavuza wamaphaphu ongewona omncane (i-NSCLC), okuguqula izimo ezazingasebenzi ngaphambili zibe ezingalawuleka ngokuhlinzwa.

I-Evolution of Lung Cancer Treatment Surgery ngo-2026

Indawo ye ukuhlinzwa ukwelashwa komdlavuza wamaphaphu iye yaba noshintsho lwepharadigm njengoba sidlula ku-2026. Ngokomlando, ukuhlinzwa kwakuvame ukuba umugqa wokuqala wokuvikela isifo sesigaba sokuqala. Kodwa-ke, ukuhlanganiswa kwemithi ye-neo-adjuvant enamandla kuye kwachaza kabusha iwindi lokuhlinzwa. Namuhla, isinqumo sokusebenza ngokuvamile sandulelwa inkambo yokwelashwa kwesistimu eklanyelwe ukukhulisa ukusebenza kahle kwenqubo elandelayo.

Lokhu kuguquka kuqhutshwa idatha yomtholampilo eqinile ebonisa ukuthi ukwelapha lesi sifo ngendlela ehlelekile ngaphambi kokulawulwa kwendawo kuholela emazingeni angcono okusinda kwesikhathi eside. Ukugxila kushintshile ekususeni nje amathumba abonakalayo kuya ekubhekaneni nokuziphatha kwebhayoloji yamangqamuzana omdlavuza ngokwawo. Odokotela abahlinzayo nama-oncologists manje basebenza emaqenjini ahlanganiswe ngokuqinile emikhakha eminingi ukuze banqume isikhathi esifanelekile sokungenelela.

Ngo-2026, incazelo yegama elithi "resectable" inwetshiwe. Izimila ezazibhekwa njengezinkulu kakhulu noma ezisondelene kakhulu nezakhiwo ezibalulekile manje zingase zehliswe ngempumelelo. Lokhu kuvumela izindlela zokuhlinza ezingavamisile futhi kugcina izicubu zamaphaphu ezinempilo. Ukusebenzisana phakathi kwe-oncology yezokwelapha nokuhlinzwa kwesifuba akukaze kube namandla, okunikeza ithemba elisha ezigulini ezinesifo esithuthuke endaweni.

Kungani I-Neo-Adjuvant Therapy Manje Isezingeni

Ukwamukelwa kokwelashwa kwe-neo-adjuvant njengesandulela esijwayelekile ukuhlinzwa ukwelashwa komdlavuza wamaphaphu isekelwe ezicini eziningana ezibalulekile. Okokuqala, ibhekana nesifo se-micrometastatic kusenesikhathi. Amangqamuzana omdlavuza avame ukusakazekela kwezinye izingxenye zomzimba ngaphambi kokuba kutholakale isimila esiyinhloko. Ngokunikeza ukwelashwa kwesistimu kuqala, odokotela bangakhomba lawa maseli afihliwe ngokushesha.

Okwesibili, inikeza ukuhlolwa kokuzwela kwe-vivo. Ukubona ukuthi isimila sishwabana kanjani noma sisabela kanjani emithini ethile ngaphambi kokuhlinzwa kunikeza odokotela ulwazi olubalulekile. Uma isimila singaphenduli, uhlelo lokwelapha lungalungiswa ngaphambi kokuhlinzwa okukhulu. Le ndlela eqondene nawe inciphisa ubungozi bokuhlinzwa okungadingekile ezigulini ezingazuza kakhulu kwezinye izindlela zokwelapha.

Okwesithathu, ukwelashwa kwe-neo-adjuvant kwandisa izinga lokukhishwa kwe-R0. Ukukhishwa kwe-R0 kusho ukuthi udokotela ohlinzayo ususa sonke isimila ngamamajini acacile, angashiyi isifo esincanyana. Ucwaningo ngo-2025 kanye no-2026 luqinisekisile ukuthi ukwelashwa ngaphambi kokuhlinzwa kukhulisa kakhulu amathuba okuthola lo mphumela ojwayelekile wegolide, oxhumene ngokuqondile namazinga aphansi okuphinda.

Ukuphumelela ku-Immunotherapy-based Neo-Adjuvant Regimens

Enye yentuthuko ebaluleke kakhulu ku ukuhlinzwa ukwelashwa komdlavuza wamaphaphu ama-protocols ukufakwa kwe-immune checkpoint inhibitors ngaphambi kokusebenza. Ngokungafani ne-chemotherapy yendabuko, ebulala ngokuqondile amangqamuzana ahlukana ngokushesha, i-immunotherapy inika amandla amasosha omzimba esiguli ukuba abone futhi ahlasele amangqamuzana omdlavuza. Uma isetshenziswa ngaphambi kokuhlinzwa, leli su libonise imiphumela ephawulekayo emazingeni okusabela kwe-pathological.

Izivivinyo zemitholampilo ezethulwe ngasekupheleni kuka-2025 nasekuqaleni kuka-2026 ziye zagqamisa ukusebenza kahle kokuhlanganisa i-PD-1 noma i-PD-L1 inhibitors ne-chemotherapy. Lezi zinhlanganisela ziholele emazingeni aphezulu e-Major Pathological Response (MPR) kanye ne-Pathological Complete Response (pCR). Ezimweni eziningi, ama-pathologists awatholi amangqamuzana omdlavuza asebenzayo esicutshini esikhishwe ngesikhathi sokuhlinzwa, into eyayingavamile eminyakeni embalwa edlule.

Lo mshini ubandakanya ukuvimba amaprotheni afana ne-PD-L1 amangqamuzana omdlavuza awasebenzisa ukucasha kuma-T-cell. Ngokukhulula la mabhuleki, amasosha omzimba asebenza kakhulu ngokumelene nesimila. Lo msebenzi uvame ukuqhubeka ngemva kokuhlinzwa, unikeza uhlobo “lwenkumbulo ye-immunological” esiza ukuvimbela ukuphindeka. Lesi senzo esikabili sokushwabanisa isimila ngaphambi kokuhlinzwa nokuvikela ngemva kokuhlinzwa sikwenza kube isisekelo sokunakekelwa kwesimanje.

Ushintsho Lokushayela Kwedatha Yesivivinyo Somtholampilo

Idatha yakamuva evela ezingqungqutheleni ezinkulu ze-oncology iqinise indima ye-immunotherapy esimweni se-neo-adjuvant. Ucwaningo olubandakanya ama-ejenti afana ne-nivolumab ne-relatlimab lubonise ukuba nokwenzeka nokuphepha. Iziguli ezithola lezi zinhlanganisela ngaphambi kokuhlinzwa zibonise amazinga aphezulu okukhishwa okuphumelelayo ngaphandle kwezinkinga zokuhlinzwa ezengeziwe.

Ngokukhethekile, ucwaningo lubonisa ukuthi ukwengeza i-LAG-3 inhibitor ku-PD-1 blockade kungathuthukisa izimpendulo. Le ndlela ehlosiwe kaningi ihlasela isimila ngokusebenzisa izindlela ezihlukene zokuzivikela komzimba. Umphumela uba ukusabela okujulile futhi okuhlala isikhathi eside, okuvumela odokotela abahlinzayo ukuba benze ukuhlinzwa okungathí sina kuyilapho begcina ukuphepha kwe-oncological.

Ngaphezu kwalokho, isikhathi salokhu kwelashwa senziwe saba ngcono. Izivumelwano zamanje ngokuvamile zihlanganisa imijikelezo emibili kuya kwemine ye-immunochemotherapy ngaphambi kokuhlinzwa. Leli windi lanele ukuheha ukuhlehla kwesimila okubalulekile ngenkathi igwema i-fibrosis eyeqile engenza ukuqaqa kube nzima. Ibhalansi phakathi kokusebenza ngempumelelo kanye nokwenzeka kokuhlinzwa kulawulwa ngokucophelela ngokusekelwe ebufakazini bakamuva.

Ukwelapha Okuhlosiwe Kweziguli Ezinempilo Yomshayeli-Mutation

Ngenkathi i-immunotherapy ibusa indawo yeziguli eziningi, lezo ezinoshintsho oluthile lwabashayeli zidinga indlela ehlukile. Kubantu abanokuguqulwa kwe-EGFR, ALK, noma i-ROS1, ama-tyrosine kinase inhibitors (TKIs) ahlosiwe aqala ukuhlanganisa namasu e-neo-adjuvant. Imihlahlandlela yango-2026 igcizelela umuthi onembayo, oqinisekisa ukuthi umuthi ofanele ufika esigulini esifanele ngaphambi kokuthi singene egunjini lokuhlinza.

Ku-NSCLC eguquliwe ye-EGFR, ama-TKI esizukulwane sesithathu afana ne-osimertinib ayahlolwa esimweni sangaphambi kokuhlinzwa. Idatha yasekuqaleni iphakamisa ukuthi lawa ma-ejenti anganciphisa ngempumelelo amathumba futhi asule ama-lymph nodes. Kodwa-ke, amazinga okuphendula okuphelele kwe-pathological nge-TKIs kuphela angase ahluke kulawo abonwa nge-immunochemotherapy. Ngakho-ke, amasu ayinhlanganisela afaka ama-TKI kanye nokwelashwa ngamakhemikhali noma ukuhlanganiswa kwendawo angaphansi kophenyo olunzulu.

Inselele ilele ekulinganiseni ukuncipha kwesimila okujulile okuhlinzekwa ama-TKIs nesidingo semajini ecacile yokuhlinzwa. Olunye ucwaningo lubonisa ukuthi nakuba izimila zincipha kakhulu, izifo ezisele zingase ziqhubeke zisesimweni sokungalali. Ngakho-ke, isinqumo sokuqhubeka nokuhlinzwa ngemva kokwelashwa kwe-neo-adjuvant okuhlosiwe sidinga ukucatshangelwa ngokucophelela nokuhlolwa kwamangqamuzana.

Iqhaza Lokwelapha Okudidiyelwe Kwasendaweni

Ngokungeziwe emithini ye-systemic, ukwelashwa okuhlangene kwendawo (LCT) kuyazuza njengengxenye ye-neo-adjuvant noma uhlelo lwe-peri-operative. I-LCT ihlanganisa amasu afana ne-stereotactic body radiation therapy (SBRT) esetshenziswa kumasayithi athile ngaphambi noma eceleni kokwelashwa kwesistimu. Le ndlela "exubile" ihlose ukukhulisa ukulawula kwendawo ngenkathi ilawula ubungozi besistimu.

Ucwaningo olwethulwa ngo-2026 lubonisa ukuthi ezigulini ezinesifo se-oligometastatic, ukuhlanganisa ukwelashwa okuhlosiwe ne-LCT kunganweba kakhulu ukusinda okungenanqubekela phambili. Lapho kulandelwa ukuhlinzwa kwesimila esiyinhloko, le ndlela yokwenza izinto eziningi inikeza ikhambi elingase libe khona ezigulini ezazithathwa njengezingelapheki ngaphambili. Imele uguquko ukusuka ekunakekelweni kokudambisa ukuya enhloso yokwelapha ezimeni ezithuthukile.

Odokotela abahlinzayo kufanele baqaphele imiphumela yemisebe yangaphambili ezindizeni zezicubu. Nakuba i-SBRT inembile, ingabangela ukuvuvukala kanye ne-fibrosis. Ukuhlelwa kwemikhakha eminingi kubalulekile ukuze kuqinisekiswe ukuthi inkundla yokukhishwa kwemisebe ayifaki engozini ukuphepha kokuhlinzwa kokuhlinzwa okulandelayo. Ukuxhumana phakathi kwama-oncologists ngemisebe kanye nodokotela abahlinza isifuba kubaluleke kakhulu kunangaphambili.

Amasu Okuhlinza kanye Nentuthuko Ehlasela Kancane

Ingxenye yokuhlinzwa ye ukuhlinzwa ukwelashwa komdlavuza wamaphaphu iye yavela futhi ngokuhambisana nemithi yokwelapha. Ukwamukelwa okusabalele kwe-Video-Assisted Thoracoscopic Surgery (VATS) kanye nezinqubo ezisizwa ngamarobhothi kuguqule ukululama kwesiguli. Ngo-2026, lezi zindlela zokuhlasela kancane ziyindinganiso ekhethwayo ezimweni eziningi ezikwazi ukubuyisela kabusha, inqobo nje uma udokotela ohlinzayo enolwazi olwanele.

Amasistimu wamarobhothi anikezela ngobuchule obuthuthukisiwe kanye nokubonwa kwe-3D, okuvumela ukuhlukaniswa okunembile ngisho nasezimeni eziyinkimbinkimbi ze-anatomical. Lokhu kunenzuzo ikakhulukazi ngemva kokwelashwa kwe-neo-adjuvant, lapho izindiza zezicubu zingashintshwa ukuvuvukala noma i-fibrosis. Ikhono lokuzulazula kulezi zinguquko ngokuphepha linciphisa izinga lokuguqulwa ukuze livule i-thoracotomy, lilondoloze izinzuzo zokuhlinzwa okungavamisile kancane.

Ngaphezu kwalokho, izinga lokukhishwa kabusha liyacwengwa. Ama-Segmentectomies kanye nokususwa kwe-wedge kwenziwa ngokuya ngokuya kumathumba amancane, aseduze, ikakhulukazi ezigulini ezinomkhawulo wamaphaphu. Ukwelashwa kwe-neo-adjuvant kuvame ukunciphisa izimila zibe usayizi lapho lezi zinqubo zokonga amaphaphu ziba nokwenzeka. Ukugcina ukusebenza kwamaphaphu kubalulekile kwikhwalithi yokuphila, ikakhulukazi ezigulini esezikhulile noma lezo ezinezifo ezihambisana ne-COPD.

Ukubaluleka kwe-Lymph Node Dissection

Kungakhathaliseki ukuthi iyiphi indlela yokuhlinzwa, i-lymph node dissection ihlala iyisici esingaxoxisana ngaso. ukuhlinzwa ukwelashwa komdlavuza wamaphaphu. Isiteji esinembile sincike ekususweni nasekuhlaziyweni kwama-lymph nodes e-mediastinal. Ukwelashwa kwe-neo-adjuvant kungabulala ama-lymph nodes, kubenze babonakale bevamile ekufanekisweni, kodwa ukuhlolwa kwe-pathological kusadingeka ukuze kuqinisekiswe impendulo.

Izinkombandlela zika-2026 zigunyaza ukukhishwa kwe-nodal okuhlelekile kukho konke ukuhlinzwa okuhloswe ukwelapha. Lokhu kuqinisekisa ukuthi noma yisiphi isifo esiyinsalela siyasuswa futhi kunikeza idatha enembile yezinqumo zokwelashwa kwe-adjuvant. Ukweqa lesi sinyathelo kungaholela ekunakekelweni kokulandelela okungafanele kanye nokulandelela okungafanele. Umgomo uhlale uwu-R0 resection, ohlanganisa ukucaciswa kwazo zonke iziteshi zama-nodal ezithintekayo.

Incazelo yesampula ye-lymph node eyanele imisiwe. Odokotela abahlinzayo kulindeleke ukuthi basampula iziteshi ezithile ngokusekelwe endaweni yesimila. Lokhu kuqina kuqinisekisa ukuvumelana kuzo zonke izikhungo futhi kuvumela ukuqhathaniswa okungcono kwemiphumela ezivivinyweni zomtholampilo. Kuyinsika eyisisekelo yokunakekelwa kwekhwalithi ephezulu ye-thoracic.

Ukukhethwa Kwesiguli kanye Nokuhlolwa Kwemikhakha Ehlukahlukene

Akusona sonke isiguli esidinga ukwelashwa kwe-neo-adjuvant okulandelwa ukuhlinzwa. Ukukhetha ngokucophelela isiguli kubalulekile ukuze kuqinisekiswe ukuphepha nokusebenza ngempumelelo. Ukuvumelana kwango-2026 kugcizelela indima yeQembu Lezinhlaka Ezihlukahlukene (MDT) ekuhloleni zonke izimo. Leli qembu ngokuvamile lihlanganisa odokotela abahlinza isifuba, odokotela bezifo zomdlavuza, odokotela be-radiation oncologists, izazi ze-radiologist, kanye nezazi zezifo.

Izici ezibalulekile ekukhethweni zifaka isimo sokusebenza, i-comorbidities, kanye ne-tumor biology. Iziguli ezinesimo esingesihle sokusebenza zingase zingakubekezeleli ukuhlanganiswa kwe-systemic therapy kanye nokuhlinzwa okukhulu. Ngokufanayo, labo abanokuzibandakanya okukhulu kwe-mediastinal noma ama-metastases akude bangadinga amasu okuphatha ahlukene. I-MDT ibuyekeza yonke imiphumela yokuthwebula ne-biopsy ukuze yenze uhlelo lomuntu siqu.

Ukuhlolwa kwe-Biomarker kuyisidingo sokuqala sokwenza izinqumo. Iphrofayili yofuzo ebanzi ikhomba abashayeli abafana ne-EGFR, KRAS, noma i-HER2, eqondisa ukukhetha kwabasebenzeli abaqondisiwe. Amazinga wokukhuluma we-PD-L1 asiza ukubikezela amathuba okuphendula ku-immunotherapy. Ngaphandle kwalo mephu womgwaqo wamangqamuzana, ukwelashwa bekuzoba ngokoqobo futhi kungaphumeleli kangako. Umuthi onembile uqala ngokuxilongwa okunembile.

Ukuhlelwa Kwengozi kanye Nokuqeqeshwa Kwangaphambili

Ngaphambi kokuqala ukwelashwa kwe-neo-adjuvant, iziguli zithola ukuhlelwa kwengozi okuphelele. Lokhu kuhilela ukuhlola ukusebenza kwenhliziyo, ukugcinwa kwamaphaphu, kanye nesimo sokudla okunempilo. Izinhlelo zokuhlinzelwa esibhedlela ziya ngokuya zituswa ukuze kuthuthukiswe iziguli ngokomzimba ngaphambi kokuba ziqale ukwelashwa. Ukuzivocavoca, ukuyeka ukubhema, kanye nokuthuthukiswa kokudla kunganciphisa kakhulu izinkinga zangemva kokuhlinzwa.

Ukuyeka ukubhema kubaluleke kakhulu. Ukuqhubeka nokubhema ngesikhathi sokwelashwa kwe-neo-adjuvant kungakhinyabeza ukuphola kwesilonda futhi kwandise ingozi yokutheleleka. Ngaphezu kwalokho, ukubhema kungase kuphazamise ukusebenza kwemithi ethile. Iziguli zelulekwa ngokuqinile ukuthi ziyeke ngokushesha ngemva kokuxilongwa ukuze kwandiswe izinzuzo zalo lonke uhambo lokwelashwa.

Ukwesekwa kwengqondo nakho kuyisici esibalulekile. Ithemba lezindlela zokwelashwa eziningi lingaba likhulu kakhulu. Amaqembu ezeluleko nawokweseka asiza iziguli ukuthi zikwazi ukubhekana nezinselele zemizwa zokuxilongwa kwazo. Isiguli esilungiswe ngokwengqondo maningi amathuba okuthi sibambelele kuzinqubo zokwelashwa futhi silulame ngokushesha ngemva kokuhlinzwa.

Ukuhlaziywa Okuqhathanisayo Kwamasu we-Neo-Adjuvant

Ukuqonda umehluko phakathi kwezindlela ezahlukahlukene ze-neo-adjuvant kusiza ekuhlanganiseni ukwelashwa ngokwezidingo zomuntu ngamunye. Ithebula elingezansi liqhathanisa amasu okuqala asetshenziswayo njengamanje ukuhlinzwa ukwelashwa komdlavuza wamaphaphu amaphrothokholi.

Lesi siqhathaniso sigqamisa ukuthi asikho isisombululo esilingana sonke. Ukuzikhethela kuncike kakhulu kuphrofayili ye-molecular of the tumor kanye ne-physiological reserve yesiguli. I-Chemo-immunotherapy isiphenduke inkambo ebusayo yamathumba ohlobo lwasendle ngenxa yezimpendulo eziphakeme ze-pathological. Kodwa-ke, ukwelashwa okuhlosiwe kuhlala kudingekile kubantu abaguquguqukayo.

Izindlela zokwelapha ezisafufusa eziphindwe kathathu zibonisa isithembiso esivivinyweni sokuqala kodwa azikabi izinga lokunakekelwa ngaphandle kocwaningo lomtholampilo. Lezi zinhlobo zemithi zihlose ukuphusha imingcele yalokho okufezwayo, okungenzeka kuguqule izehlakalo eziningi ezibuyekezwayo ezisemngceleni. Njengoba idatha ikhula, lezi zinketho zingase zandise isethi yamathuluzi etholakalayo kubahlengikazi.

Ukuphatha Ubuthi kanye Nesikhathi Sokuhlinzwa

Isici esibalulekile sokuhlanganisa ukwelashwa kwe-neo-adjuvant ne ukuhlinzwa ukwelashwa komdlavuza wamaphaphu ilawula ubuthi. Ukwelashwa okuhlelekile kungabangela imiphumela engemihle ethinta ukulungela ukuhlinzwa. Izehlakalo ezimbi ezihlobene namasosha omzimba (i-irAEs) njenge-pneumonitis noma i-colitis kufanele zihlonzwe futhi zilawulwe ngokushesha ukuze kugwenywe ukubambezeleka kokuhlinzwa.

Isikhathi siyikho konke. Isikhawu phakathi komthamo wokugcina we-neo-adjuvant therapy kanye nokuhlinzwa sibalwa ngokucophelela. Ngokuvamile, ukuhlinzwa kuhlelwe amaviki angu-3 kuya kwangu-6 ngemva komjikelezo wokugcina. Leli windi livumela ubuthi obunamandla ukuthi buxazulule ngenkathi kugcinwa umphumela wokwelapha. Ukusebenza ngokushesha kungandisa izinkinga, kuyilapho ukulinda isikhathi eside kubeka engcupheni yokukhula kabusha kwesimila.

Odokotela abahlinzayo kufanele baqaphele izimpawu zobuthakathaka bezicubu noma ukunamathela okungalindelekile okubangelwa ukwelashwa kwangaphambili. Imiphumela yokuhlinzwa ingase yehluke emfanekisweni wangaphambi kokuhlinzwa. Ukuvumelana nezimo nolwazi kuyadingeka ukuze uvumelane nohlelo lokuhlinza ngesikhathi sangempela. Umgomo uwukufinyelela ukukhishwa kabusha okuphelele ngaphandle kokuyekethisa ukuphepha kwesiguli.

Ukunakekelwa Kwangemva Kokuhlinzwa kanye Nezinqumo Ze-Adjuvant

Uhambo alupheli ngokuhlinzwa. Ukunakekelwa kwangemva kokuhlinzwa kuklanyelwe ngokusekelwe ekuphenduleni kwe-pathological ku-neo-adjuvant therapy. Iziguli ezithola impendulo ephelele ye-pathological (pCR) zingase zibe nesimiso sokulandelela esihlukile uma kuqhathaniswa nalabo abanesifo esisele. Izinga lesimila esisebenzayo esisalayo liyisibikezelo esinamandla sokuphinda kwenzeke esikhathini esizayo.

Izinqumo zokwelashwa kwe-Adjuvant manje seziyinkimbinkimbi kakhulu. Ezigulini ezithole i-neo-adjuvant immunotherapy futhi zathola impendulo enhle, ukuqhubeka nokwelashwa kwamasosha omzimba ngemva kokuhlinzwa kuvame ukutuswa ukuze kuhlanganiswe inzuzo. Le ndlela “yesemishi” ikhulisa isikhathi sokuchayeka kwamasosha omzimba. Ngokuphambene, uma ukukhula kwenzeka ngesikhathi sokwelashwa kwe-neo-adjuvant, ukushintshela esigabeni esihlukile semithi kuyadingeka.

Amaphrothokholi okuqapha nawo abuyekeziwe. Ukuthwebula izithombe okuvamile kanye nokuqapha kwe-biomarker kubalulekile ukuze kutholwe izimpawu zokuqala zokuvela futhi. Ukusetshenziswa kwe-liquid biopsies (ctDNA) sekuqala ukuduma ngokuthola ukubuyela emuva kwamangqamuzana ngaphambi kokuthi kubonakale ezikeni. Lokhu kuvumela ukungenelela kwangaphambili kanye nemiphumela engase ibe ngcono.

Izikhombisi-ndlela zesikhathi esizayo kanye nobuchwepheshe obusafufusa

Uma sibheka ngale kuka-2026, inkambu ye ukuhlinzwa ukwelashwa komdlavuza wamaphaphu iyaqhubeka nokuthuthuka ngokushesha. I-Artificial Intelligence (AI) isiqala ukudlala indima ekubikezeleni impendulo ekwelashweni kwe-neo-adjuvant. Ama-algorithms ahlaziya izici ze-radiomic ezivela kuma-CT scan angabikezela ukuthi yiziphi iziguli okungenzeka zizuze i-pCR, zisize ekukhetheni ukwelashwa.

Izigaba ezintsha zezidakamizwa, njenge-Antibody-Drug Conjugates (ADCs), zingena endaweni ye-neo-adjuvant. Lawa ma-molecule aletha i-chemotherapy enamandla ngokuqondile kumaseli omdlavuza, esindisa izicubu ezinempilo. Izivivinyo zangaphambi kwesikhathi ziphakamisa ukuthi zingaba abashintshi begeyimu ezigulini ezingaphenduli ku-immunochemotherapy evamile. Ukuhlanganiswa kwabo ekuhambeni komsebenzi wokuhlinza kulindeleke eminyakeni ezayo.

Ukwengeza, umqondo "wokulondolozwa kwezitho" ucutshungulwa kakhulu. Ezigulini ezikhethiwe ezinezimpendulo ezinhle kakhulu, ukuhlinzwa okungatheni noma ngisho nokuphathwa okungahlinzeki kungase kucatshangelwe esikhathini esizayo. Nakuba ukuhlinza kuseyindinganiso eyigolide yokwelapha, incazelo yokwelapha iyanda ukuze ihlanganise izindlela eziphumelela kakhulu ezingahlaseli.

Umthelela Wemininingwane Yofuzo Ekuhlinzeni

Iphrofayili yofuzo ebanzi isiba yinjwayelo ngaphambi kwanoma yisiphi isinqumo sokwelashwa. Ukuhlonza ukuxubana okungavamile okufana ne-NRG1 noma i-MET amplifications kuvula iminyango yemithi ethile eqondiwe. Njengoba uhlu lwezinhloso ezingenziwa lukhula, i-algorithm yokuhlinzwa iba yinkimbinkimbi kakhulu kodwa futhi icace kakhudlwana. Odokotela abahlinzayo kufanele bahlale benolwazi lwakamuva mayelana nokutholwa kwamangqamuzana ukuze banikeze ukunakekelwa okungcono kakhulu.

Ukusebenzisana phakathi kofuzo kanye ne-immune microenvironment kungenye indawo yocwaningo olunzulu. Ukuqonda ukuthi kungani ezinye izimila “zishisa” (amasosha omzimba) kanti ezinye “ziyabanda” kusiza ekwakhekeni kwemithi ye-neo-adjuvant engcono. Ukuguqula izimila ezibandayo zibe ezishisayo ngaphambi kokuhlinzwa kungavula izinzuzo ze-immunotherapy kubantu abaningi.

Ekugcineni, ikusasa lilele ekwenzeni kube ngokwakho. Umdlavuza wesiguli ngasinye uhlukile, futhi kufanele kube kanjalo nendlela yabo yokwelapha. Ukuhlangana kokuxilongwa okuthuthukile, izindlela zokwelapha ezinoveli, kanye namasu okuhlinza acolisisiwe kuthembisa ikusasa lapho umdlavuza wamaphaphu ukhula uba yisimo esilawulekayo, futhi esivame ukulapheka.

Imibuzo Evame Ukubuzwa Mayelana Nokunakekelwa Komdlavuza Wamaphaphu We-Neo-Adjuvant

Iziguli kanye nemindeni bavame ukuba nemibuzo eminingi lapho bebhekene nokuxilongwa okubandakanya ukuhlinzwa ukwelashwa komdlavuza wamaphaphu. Ukubhekana nalokhu kukhathazeka kusiza ekudambiseni ukukhathazeka futhi kuqinisekisa imvume enolwazi. Ngezansi kunezimpendulo zemibuzo evamile esekelwe ekuvumelaneni kwamanje kwezokwelapha.

• Ingabe i-neo-adjuvant therapy ibambezela ukuhlinzwa? Nakuba kwengeza isikhathi ngaphambi kokuhlinzwa, ukubambezeleka kwenziwa ngamabomu futhi kunenzuzo. Ivumela ukuncipha kwesimila kanye nokulawulwa kwesistimu, okugcina kuthuthukisa impumelelo yokuhlinzwa nokuphila isikhathi eside.
• Ingabe ukuhlinzwa kusengenzeka uma isimila singancipha? Yebo, ezimweni eziningi. Ngisho nangaphandle kokuncipha okuphawulekayo, ukwelapha kungase kubulale izifo ezincane kakhulu. Ithimba labahlinzayo lizophinde lihlole ukuhleleka kabusha ngokusekelwe kumfanekiso obuyekeziwe kanye nesimo somtholampilo.
• Iyini imiphumela emibi yokwelashwa kwangaphambi kokuhlinzwa? Imiphumela emibi evamile ihlanganisa ukukhathala, isicanucanu, nezindaba ezihlobene nokuzivikela komzimba njengokuqubuka noma ukungasebenzi kahle kwegilo. Iningi liyalawuleka ngokunakekelwa okusekelayo futhi akuvimbeli ukuhlinzwa.
• Kuthatha isikhathi esingakanani ukululama ngemva kokuhlinzwa kulandela ukwelashwa kwe-neo-adjuvant? Izikhathi zokululama ziyahlukahluka kodwa ngokuvamile zifana nokuhlinzwa kuphela, ikakhulukazi ngamasu angenele kancane. Izinqubo zokutakula ezithuthukisiwe zisiza iziguli ukuthi zibuyele emisebenzini evamile ngokushesha.

Ukuxhumana okuvulekile nethimba lokunakekelwa kwezempilo kubalulekile. Iziguli kufanele zizizwe zinamandla okubuza mayelana nesizathu sohlelo lwazo oluthile lokwelashwa. Ukuqonda izinjongo zokwelashwa kwe-neo-adjuvant kukhuthaza ukwethembana nokubambisana, okubalulekile ekuzuleni ubunzima bokunakekelwa komdlavuza.

Isiphetho: Inkathi Entsha Yeziguli Zomdlavuza Wamaphaphu

Unyaka wezi-2026 uphawula inkathi yenguquko ukuhlinzwa ukwelashwa komdlavuza wamaphaphu. Ukuhlanganiswa okungenamthungo kwe-neo-adjuvant immunotherapy kanye nama-ejenti ahlosiwe kuye kwakhuphula izinga lokunakekela, kunikeze amathuba angakaze abonwe okwelapha. Iziguli ezake zabhekana nezinketho ezilinganiselwe manje sezikwazi ukufinyelela kumasu ayinkimbinkimbi, anezimo eziningi ezibhekana nesifo sendawo kanye nesistimu.

Ukusebenzisana phakathi kwama-oncologists wezokwelapha kanye nodokotela abahlinza isifuba akukaze kube okubucayi kakhulu. Ndawonye, ​​bazulazula enkingeni ye-algorithms yokwelapha yesimanje ukuletha ukunakekelwa komuntu siqu. Njengoba ucwaningo luqhubeka nokwembula imininingwane emisha kanye nezindlela zokwelapha, ukubikezelwa kweziguli ezinomdlavuza wamaphaphu kuyaqhubeka nokuba ngcono kancane kancane.

Kunoma ubani obhekene nalokhu kuxilongwa, umlayezo ucacile: ithemba lingokoqobo, futhi intuthuko iyabonakala. Ngenhlanganisela efanele yesayensi esezingeni eliphezulu kanye nokunakekelwa kokuhlinzwa kochwepheshe, ukunqoba umdlavuza wamaphaphu kufinyeleleka kakhulu kunangaphambili. Uhambo luyinselele, kodwa indawo oya kuyo—ukuphila okungenawo umdlavuza—ifinyeleleka kwabaningi.